Update on first-line treatment of advanced ovarian carcinoma.
Update on first-line treatment of advanced ovarian carcinoma.
复制标题
DOI：
10.2147/ijwh.s30231
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Ledermann J
中科院分区：
文献类型：
--
作者：
Kemp Z;Ledermann J
尽管晚期卵巢癌一线治疗的反应率很高，但绝大多数患者会复发。多年来，最大减瘤手术和铂金双联化疗一直是护理标准，新方法势在必行。最近的临床试验给人们带来了希望。新辅助化疗、腹腔内给药和剂量密集策略都显示出有希望的结果，靶向血管生成也是如此。对卵巢癌分子格局的更深入了解有助于确定新的治疗方案。在这篇综述中，我们将重点介绍这些领域的关键试验和最新进展。
Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patients relapse. Maximal debulking surgery and chemotherapy with a platinum doublet have remained the standard of care for many years and new approaches are imperative. Recent clinical trials have given grounds for hope. Neoadjuvant chemotherapy, intraperitoneal delivery, and dose-dense strategies have all shown promising results, as has the targeting of angiogenesis. A greater understanding of the molecular landscape of ovarian cancer is helping to identify new treatment options. In this review, we will highlight the key trials and recent progress in these areas.